surmount-1 trial tirzepatide weight loss non-diabetic for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled SURMOUNT-1: In an RCT, adults

One of the biggest benefits

Findings: RCTSURMOUNT-MAINTAIN - Tirzepatide for Maintenance of Bodyweight Reduction in Obesity, Lancet (2026) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=378 | length = 112 weeks) in adults with obesity who completed 60 weeks of open-label tirzepatide at the maximum tolerated dose (10 or 15 mg once weekly) Treatment: Continue tirzepatide maximum tolerated dose (MTD

Exposure to excessive heat can significantly compromise the therapeutic integrity of Ozempic

You should skip these injections if you: Are pregnant or breastfeeding

The benefits of subcutaneous GLP-1 in type 2 diabetes have already been clearly demonstrated

Restriction: GLP-1 can contribute to malnutrition and electrolyte imbalances because its effects on appetite can make restrictive eating and weight loss more severe.Any medicine that alters hunger cues, including GLP-1 meds for weight loss, should be approached with caution and coordinated care when there are concerns about GLP-1 and eating disorders